Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California
blank

 

Recent News and Articles on the Keywords: neuropathic pain + nhs scotland + lyrica  Related to the article below (Last Update: 7/1/2008)

XTL Biopharmaceuticals Announces Completion of Patient ...
FOXBusiness -
The Phase 2b trial is aimed at demonstrating the efficacy of Bicifadine in diabetic neuropathic pain, using a study design that is similar to the successful ...XTLB - OTC:CMTX
Marijuana may help ease nerve pain
Times of India, India - Jun 27, 2008
In the study involving thirty-eight patients, researchers examined whether marijuana produces analgesia for patients with neuropathic pain. ...
Company's End-of-Phase II Meeting with FDA Set for Sept. 29
PharmaLive.com (press release), PA -
These include migraine and other forms of chronic pain such as neuropathic pain and fibromyalgia, as well as muscle spasticity and rigidity, thrombosis and ...TPTX
Depomed to borrow $15 million for hot flash drug
Bizjournals.com, NC -
Menlo Park-based Depomed (NASDAQ: DEPO) is developing its drug Gabapentin GR to treat both neuropathic pain and menopausal hot flashes. ...
Marijuana may help ease nerve pain
TopNews, India - Jun 25, 2008
In the study involving thirty-eight patients, researchers examined whether marijuana produces analgesia for patients with neuropathic pain. ...
Pot May Ease Nerve Pain, Study Shows
CBS News, NY - Jun 26, 2008
They studied 38 adults with nerve pain (neuropathic pain) who had smoked pot in the past but abstained from smoking marijuana for 30 days before the study. ...
Neuropathic pain research award recipients announced
Laboratory Products News, Canada - Jun 16, 2008
Kirkland, QC - Pfizer Canada has announced the recipients of their first Neuropathic Pain Research Awards Competition. This grant competition aims to fund ...
Pipeline and Commercial Insight: Neuropathic Pain
Pharmaceutical Business Review - Jun 12, 2008
The neuropathic pain market is forecast to almost triple to over $6.3 billion by the end of the forecast period in 2017. The growth in the market is spurred ...
UPDATE 1-UCB to decide on lacosamide tests by year end
Reuters - Jun 24, 2008
Lacosamide has already been filed with the United States and Europe for the treatment of epilepsy and diabetic neuropathic pain.
Act early or post-surgical pain persists
6minutes, Australia - Jun 17, 2008
by Dr Linda Calabresi Persistent neuropathic pain is a relatively common complication of surgery, but one that is largely unrecognised, according to a ...
Source: Google News

[PDF] Pregabalin?a New Treatment for Partial Epilepsy and Neuropathic Pain
S Africa - Seizure - acnr.co.uk
... Both neuropathic pain and epilepsy are notoriously complex and ... Hospital, 1345 Govan
Road, Glasgow, G51 4TF, Scotland. ... Email: JohnPaul.Leach@sgh.scot.nhs.uk ...

[PDF] Sino-British Joint Conference on Neurology
DJ Burn, N upon Tyne - ACNR - acnr.co.uk
... 1, 2, 3 Both neuropathic pain and epilepsy are notoriously complex and challenging ...
Southern General Hospital, 1345 Govan Road, Glasgow, G51 4TF, Scotland. ... nhs. ...

?????????? ??????????????? ???????????????? ?????????? ???????????
?? ?????????, ? ???? - consilium-medicum.com
... LYRICA Study Group Pregabalin for peripheral neuropathic pain: results of a multicenter ...
Management of chronic pain in adults ... NHS Quality Improvement Scotland 2006 ...

??????????????? ???????????????? ?????????? ??????????? -
?? ?????????, ? ???? - consilium-medicum.com
... LYRICA Study Group Pregabalin for peripheral neuropathic pain: results of a multicenter ...
Management of chronic pain in adults ... NHS Quality Improvement Scotland 2006 ...

Safety of antiepileptic drugs during pregnancy -
SJ Hunt, JI Morrow - Expert Opin. Drug Saf., 2005 - Expert Opinion
... It is also used in the control of neuropathic pain and bipolar affective disorder.
Page 3. ... It is now more commonly used for the treatment of neuropathic pain. ...

[PDF] days
NN PHARMACEUTICALS - britishpainsociety.org
... Mildred B Clulow Award Payment by Results The Pain Cookbook: a BPS and voluntary
sector seminar Introduction to ... relief from severe OA pain days ...

[PDF] Newsletter -
IC PAIN - britishpainsociety.org
... POMMarketing Authorisation Numbers EU/1/04/296/001 EU/1/04/296/002EU/1/04/296/003
EU/1/04/296/004 Basic NHS Cost ?22.40 ... s pain. hing. ... peripheral neuropathic ...

[PDF] Anaesthesia News
HA Everest - aagbi.org
... mantra Om Mane Padme Hum (roughly translated as ?hail the jewel in the lotus?) soon
became the signature lyric for the ... 1. NHS Modernistation Agency, 2004. ...

Complementary and Alternative Medicine -
J Filshie, CNJ Rubens - Anesthesiology Clinics of North America, 2006 - Elsevier
... tetrahydrocannabinol dronabinol on central neuropathic pain in patients ... listening,
discussion of lyrics, improvisation, and ... reduce symptoms of pain and sickness ...

[PDF] pharmacist
AMD Managing - irishpharmacist.ie
... any adverse effects have emerged.The initiative follows the agreement earlier this
year between pharmacists and the National Health Service (NHS) regarding the ...

Source: Google Scholar
 
 

Peripheral neuropathic pain: Lyrica is not recommended for use within NHS Scotland

 
 
The Scottish Medicines Consortium ( SMC ) has advised NHS ( National Health Service ) Boards and Area Drug and Therapeutic Committees ( ADTCs ) that Pregabalin ( Lyrica ) is not recommended for use within NHS Scotland for the treatment of peripheral neuropathic pain in adults.

Comparative clinical and cost effectiveness have not been demonstrated.


Evidence on comparative efficacy

Pregabalin is an antiepileptic that decreases central neuronal excitability by binding to an auxillary subunit of a voltage-gated calcium channel in the central nervous system.
It also reduces the release of several neurotransmitters including glutamate, noradrenaline and substance P, though the significance of the latter effects is unknown.

The original submission to the Scottish Medicines Consortium, included data from ten double-blind studies. Five studies recruited patients with diabetes who had glycated haemoglobin ( HbA1C ) less than or equal to 11 percent and distal symmetrical sensorimotor polyneuropathy for more than or equal to 1 year and < 5 years in three studies. Four studies recruited patients with postherpetic neuralgia of more than or equal to 3 and 6 months duration after healing of the herpes zoster skin rash.
A further double-blind trial recruited patients with either diabetic peripheral neuropathy or postherpetic neuralgia.

In all studies patients had a score of more than or equal to 40mm on the 100mm visual analogue pain scale of the Short-Form McGill Pain Questionnaire ( SF-MPQ ) and during the week before randomisation, had at least four daily pain scores more than or equal to 4 assessed on an 11-point scale ( where 0 = no pain and 10 = worst possible pain ).
Patients were randomised to placebo or Pregabalin with one trial including Amitriptyline as an active treatment arm. The primary endpoint, weekly mean pain score ( assessed via the 11-point Likert scale ) at endpoint, was compared in the intention to treat population between placebo and active treatments via an analysis of covariance which adjusted for weekly mean pain score at baseline.

In the trial with an active comparator, Pregabalin 600 mg daily was not associated with a significant difference from placebo in the primary analysis of pain scores at end-point. The difference between Amitriptyline 75mg daily and placebo was significant. This pattern was repeated in two supplementary analyses of pain scores and in a number of secondary end-points including the proportion of patients achieving a response ( more than or equal to 50 percent reduction in pain scores ) and patients’ and clinicians’ global impression of pain. In no endpoint analysis was the result significant for Pregabalin but not Amitriptyline.

Pregabalin 300mg and 600mg were associated with significantly lower weekly mean pain scores at endpoint compared with placebo in all other studies, except for the 300mg dose in a 12-week diabetic neuropathy study. Weekly mean pain scores with Pregabalin 150mg were generally lower than placebo, but differences between this dose and placebo were not consistently significant.
In these studies, responders were defined as patients who had a 50% reduction in mean weekly pain score compared with baseline.
Similar efficacy patterns were observed in this secondary endpoint.

The resubmission and IRP ( Independent Review Panel ) contains additional data from an interim, 15 month, analysis of an ongoing open-label safety study.
Patients had participated in previous Pregabalin studies and had a score of more than or equal to 40mm on the 100mm visual analogue pain scale of the SF-MPQ and were intolerant of or had experienced lack of efficacy after more than or equal to two weeks of at least minimum doses of tricyclic antidepressants, Gabapentin 1800mg or other third line agents. Patients were given Pregabalin 150-600mg daily and could continue to receive other analgesics, including those that may not have provided adequate pain control previously with titration at the investigator’s discretion to optimise pain control.
Pregabalin was discontinued quarterly for 3-28 days until patient’s pain worsened before recommencing. If pain did not worsen or only slightly deteriorated, the patient was discontinued from the study.

Interim analysis data from 45 patients with painful diabetic peripheral neuropathy and 36 patients with postherpetic neuralgia indicate that mean SF-MPQ scores decreased from respective baseline values of 73mm and 75mm to 47mm and 51mm at endpoint.

A published systematic review, new to the IRP, calculates numbers needed to treat ( NNT ) to achieve a 50% reduction in pain scores and numbers needed to harm ( NNH ) and uses these as a basis for an evidence-based treatment algorithm.
Data are included from five of the Pregabalin studies from above: three in painful diabetic peripheral neuropathy and two in postherpetic neuralgia.
The authors report a combined NNT for Pregabalin at doses of 150-600mg in both pain models of 4.2.
This is reported to be similar to the NNT for Gabapentin at all doses and pain models (5.1 ).
The NNH for Pregabalin was considered to represent a relatively high rate of withdrawal and was 11.7 compared with 26.1 for Gabapentin. For a treatment algorithm in peripheral neuropathic pain based on pain relief, the NNT are lowest for tricyclic antidepressants, then opioids, then Tramadol, then Gabapentin/Pregabalin.


Evidence on comparative safety

Pregabalin is commonly associated with central nervous system adverse events similar to most antiepileptic drugs. It is not metabolised in vivo and is eliminated from the systemic circulation primarily by renal excretion of the unchanged drug. It does not bind to plasma proteins and does not induce or inhibit hepatic enzymes. It would thus not be expected to induce or be affected by hepatic pharmacokinetic interactions and did not interact with other antiepileptic drugs or combined oral contraceptives in studies.
Similarly Gabapentin is eliminated renally and does not induce hepatic enzymes or interact with other antiepileptics or oral contraceptives.
However, Carbamazepine is metabolised by and induces the production of hepatic enzymes, and, thus, may be involved in hepatic pharmacokinetic interactions.


Clinical effectiveness issues

There are no direct trials of Pregabalin with Gabapentin in the treatment of neuropathic pain and so relative efficacy is uncertain. In addition, there are limited data in patients unresponsive to Gabapentin since many of the double-blind studies excluded patients who had failed to respond to previous treatment with Gabapentin more than or equal to 1200mg/day.
Since the drugs are considered to act in the same way, this exclusion could potentially favour the results of the Pregabalin studies.
Data represented in the resubmission and IRP include interim results of an open-label trial in patients intolerant of or refractory to other treatments. Although this indicates a reduction in pain with Pregabalin, these results are difficult to interpret due to a number of limitations. The study was descriptive with no statistical testing to assess efficacy; patients could remain on other analgesic medication with doses titrated to optimise control. Results from a new systematic review would suggest comparable efficacy to Gabapentin.

Source: Scottish Medicines Consortium, 2006
 
 
 
Google
Web www.iconocast.com
 
 
 

 

Continue News With: News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services. Home

 © 2002-2006

Keywords::

Contact Iconocast

Home Page